['solid tumor', 'non-small cell lung cancer metastatic']
['ensartinib']

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy

          -  For the expanded cohort portion of the study, patients must have NSCLC with ALK
             genomic alterations positive by FISH or IHC

          -  Eastern Cooperative Group ECOG) Performance Status score of 0 or 1

          -  Adequate organ system function

          -  Male patients willing to use adequate contraceptive measures; female patients who are
             not of child-bearing potential, and female patients of child-bearing potential who
             agree to use adequate contraceptive measures

          -  Measurable disease per RECIST

          -  Willingness and ability to comply with the trial and follow-up procedures

          -  Written informed consents are required to indicate that the patients are aware of the
             investigational nature of the study

        Exclusion Criteria:

          -  Current use of anticancer therapy.

          -  Use of an investigational drug within 14 days or 5 half-lives (whichever is shorter)
             prior to the first dose of ensartinib

          -  Any major surgery, radiotherapy, or immunotherapy within the last 21 days.

          -  Chemotherapy regimens with delayed toxicity within the last 4 weeks.

          -  Chemotherapy regimens given continuously or on a weekly basis with limited potential
             for delayed toxicity within the last 2 weeks.

          -  Prior stem cell transplant

          -  Patients with a known allergy or delayed hypersensitivity reaction to drugs chemically
             related to ensartinib or to the active ingredient of ensartinib

          -  Prior use of ALK TKIs with the exception of crizotinib

          -  Primary CNS tumors or meningeal metastasis

          -  Pregnant or breastfeeding female

          -  Presence of active gastrointestinal (GI) disease or other condition that will
             interfere significantly with the absorption, distribution, metabolism, or excretion of
             ensartinib

          -  Clinically significant cardiovascular disease.

          -  Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol

          -  Concurrent condition evaluated by investigator would jeopardize compliance with the
             protocol or would impart excessive risk associated with study participation that would
             make it inappropriate for the patient to be enrolled

          -  Inability or unwillingness to comply with study and/or follow-up procedures outlined
             in the protocol
      